High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 901–960 of 960
Reduction of exacerbations of COPD under long-term administration of N-acetylcysteine
Avdeev, S. N. (2007) · PULMONOLOGIYA · doi:10.18093/0869-0189-2007-0-3-89-97
Idiopathic Pulmonary Fibrosis Clinical Trials: Evolving Concepts
Martínez, F. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_20 · Cited by 1
The Role of Mesenchymal Stromal Cells in Inflammation and Treatment of Pulmonary Fibrosis
Cahill, E. (2014) · Maynooth University ePrints and eTheses Archive (Maynooth University)
Westin, E. R., Klingelhutz, A. J., Wallrath, L. L., McCray, P. B., Davidson, B. L., & Knudson, C. M. (2010) · doi:10.17077/etd.2xq96sz4
Altalag, A., ROAD, J. D., Wilcox, P., Dhillon, S. S., & Guenette, J. A. (2018) · In clinical practice · doi:10.1007/978-3-319-93650-5_9
Respiratory Homeostatic Dysfunction, Lower Respiratory Tract Dysfunction
(2014) · CRC Press eBooks · doi:10.1201/b17276-4
Amini, A., Masoumi-Moghaddam, S., & Morris, D. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-28570-2_4 · Cited by 1
Molyneaux, P. L., Nicholson, A. G., Hirani, N., & Wells, A. U. (2020) · doi:10.1093/med/9780198746690.003.0415
Self-citationHagmeyer, L., & Kolb, M. R. J. (2016) · Springer eBooks · doi:10.1007/978-3-662-48419-7_11
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00018-2
Pneumopathies interstitielles diffuses
Nunès, H., & Uzunhan, Y. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70052-0
Raghu, G., & Johnson, W. C. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00023406
“Or to summarise these concerns using a question: will it be possible to generalise these trials in a general pulmonary care practice [ 2 ]?”
InfluentialLa fibrose pulmonaire idiopathique
Uzunhan, Y. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70126-9 · Cited by 1
Behr, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-54676-1_376-1
Self-citationMunger, J. S., & Rom, W. N. (2008) · Molecular pathology library · doi:10.1007/978-0-387-72430-0_46
Valeyre, D., & Uzunhan, Y. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70066-0
Quantitative imaging analysis: challenges and potentials
Refaee, T. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220712tr
Organization of Protective Regime for Elderly Population in the COVID-19 Pandemic Period
Yakushin, M. A., Горенков, Р. В., Vasilieva, Т. P., Melerzanov, A., Aleksandrova, O. Y., Яроцкий, С. Ю., Malakhova, A. R., Москалев, А. И., & Bischof, E. Y. (2021) · Austin Journal of Public Health and Epidemiology · doi:10.26420/austinjpublichealthepidemiol.2021.1116
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis – An Update
Spagnolo, P., Nunès, H., & Wuyts, W. A. (2013) · EMJ Respiratory · doi:10.33590/emjrespir/10314639
Miziev, I. A., Makhov, M. K., Gubzhokova, A. B., Kardanov, A. A., & Kardanova, L. D. (2023) · Disaster Medicine · doi:10.33266/2070-1004-2023-2-45-50
Veit, T., & Behr, J. (2023) · Zeitschrift für Pneumologie · doi:10.1007/s10405-023-00525-w
“Die früher einge-setzte immunmodulatorische und antioxidative Therapie, die in der placebokontrol-liertenPANTHER-Studieuntersuchtwurde, soll aufgrund einer erhöhten Mortalitäts-und Hospitalisationsrate nicht mehr eingesetzt werden [5, 14, 29].”
BackgroundSelf-citationHuang, J., Su, L., Wu, D., & Yuan, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4820805/v1
MUCOLYTICS IN COPD: THE PLOT THICKENS?
(2007) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520073701027
Interstitial Lung Diseases (ILDS)
Borkar, Y. R., Salve, M. S. K., & Kitukale, M. D. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-23024
Tabaj, G. C. (2014) · Redalyc (Universidad Autónoma del Estado de México)
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611226
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611220
Zhang, X.-L., Cao, Y., & Zheng, B. (2023) · Figshare · doi:10.6084/m9.figshare.24669857
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646808
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646826
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646817
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611223
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646829
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646805
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646811
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646820
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.24670286
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646849
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611217
Shi, H., Yin, D., Bonella, F., Kreuter, M., Oltmanns, U., Li, X., Peng, S., & 魏路清 (2020) · Figshare · doi:10.6084/m9.figshare.12269687
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646840
Feng, H., Moriyama, T., Ohuchida, K., Sheng, N., Iwamoto, C., Shindo, K., Shirahane, K., Ikenaga, N., Nagai, S., Nakata, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14429282
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646834
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646843
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646837
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646823
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646832
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646846
Zhang, X.-L., Cao, Y., & Zheng, B. (2024) · Figshare · doi:10.6084/m9.figshare.26646814
Yin, Y., Wu, X., Liu, Z., Luo, Y., Jing, M., Jing, K., Li, Q., Wang, F., & Huang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761899 · Cited by 1
“Ultimately, 121 articles met all inclusion criteria (Demedts et al., 2005; Zhang et al., 2005; Bai and Wu, 2006; Liu and Qiu, 2006; Wang and Wang, 2006; Wang and Li, 2006; Nan, 2007; Zhigang et al., 2008; Jiang et al., 2009; Zhu et al., 2009; Huang et al., 2010; Taniguchi et al., 2010; Zuo et al.,…”
Ngangue, E. C.-N. (2012) · theses.fr (ABES) · doi:10.70675/b9e28642z5037z4fceza4d6za62be310d18d · Cited by 1
Traitement de la fibrose pulmonaire idiopathique : Rôle de TRIM33 et de l’inhibition d’HSPB5
Boutanquoi, P. (2019) · theses.fr (ABES) · doi:10.70675/968e196dz45c0z4010za2dez22d692e030cc
Zhu, Y., Ke, Z., Zhang, T., Sun, S. X., & Fan, X. Q. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135124
Ramadan, A. M., Wakeel, L. M. E., Adel, A., Abdel‐Wahab, M., & Fahmy, S. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05157-x · Cited by 1
BindingDB (2019) · UC San Diego · doi:10.7270/q29c70v2
Investigating xanthine oxidase toxicity models in cultured cerebellar granule neurons.
Al-Gonaiah, M. A. (2009) · Enlighten: Theses (The University of Glasgow)
Interstitielle Lungenerkrankungen
Behr, J. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50109-6
Self-citationVuorinen, K. (2008) · Helda - University of Helsinki Institutional Repository
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.